Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galeterone - Eledon Pharmaceuticals

Drug Profile

Galeterone - Eledon Pharmaceuticals

Alternative Names: TOK-001; VN/124; VN/124-1

Latest Information Update: 22 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokai Pharmaceuticals
  • Developer Novus Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers; Steroid 17-alpha-hydroxylase inhibitors; Ubiquitin thiolesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 13 Mar 2023 LTN Pharm terminates a phase II ARMOR2 trial in Prostate Cancer (Hormone refractory) (PO) in the US and Canada upon recommendation from the study's Data Monitoring Committee and lack of efficacy (NCT01709734)
  • 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
  • 09 Aug 2017 Discontinued - Phase-I for Prostate cancer (Treatment-resistant) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top